Deficiency of M2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 2, 2008, Pages

  LaCroix, Carly ^a   Freeling, Jessica ^a   Giles, Alese ^a   Wess, Jürgen ^b   Li, Yi Fan ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cardiac; Contractility; Isoproterenol; Matrix metalloproteinase; Muscarinic

Indexed keywords

BETHANECHOL; ISOPRENALINE; MATRIX METALLOPROTEINASE; MUSCARINIC M2 RECEPTOR; PHENYLEPHRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MUSCARINIC AGENT; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; VASOCONSTRICTOR AGENT;

ADRENERGIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLUS INJECTION; CARDIOVASCULAR DISEASE; CELL CULTURE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST; HEART AFTERLOAD; HEART FAILURE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART RATE; HEART STRESS; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE FUNCTION; HYPERTENSION; INHIBITION KINETICS; KNOCKOUT MOUSE; MALE; MOUSE; NEWBORN; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; REGULATORY MECHANISM; WILD TYPE; ADRENERGIC SYSTEM; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; CHRONIC DISEASE; DRUG EFFECT; GENETICS; HEART; HEART VENTRICLE; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; STRESS; WESTERN BLOTTING;

ADRENERGIC BETA-AGONISTS; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; CELLS, CULTURED; CHRONIC DISEASE; HEART; HEART RATE; HEART VENTRICLES; ISOPROTERENOL; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCARINIC AGONISTS; MYOCYTES, CARDIAC; PHENYLEPHRINE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STRESS; SYMPATHETIC NERVOUS SYSTEM; TISSUE INHIBITOR OF METALLOPROTEINASES; VASOCONSTRICTOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 39149118602     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00724.2007     Document Type: Article

References (61)

1. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113: 2089-2096, 2006.
2. Amano M, Kanda T, Ue H, Moritani T. Exercise training and autonomic nervous system activity in obese individuals. Med Sci Sports Exerc 33: 1287-1291, 2001.
3. Bohm M, Ettelbruck S, Flesch M, van Gilst WH, Knorr A, Maack C, Pinto YM, Paul M, Teisman AC, Zolk O. Beta-adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy. Cardiovasc Res 40: 146-155, 1998.
4. Brauer PR. MMPs-role in cardiovascular development and disease. Front Biosci 11: 447-478, 2006.
5. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45: 657-687, 2005.
6. Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 91: 776-781, 2002.
7. Bunag RD, Krizsan D, Itoh H. Diminished cardiovascular responsiveness to vagal stimulation in obese rats. Am J Physiol Regul Integr Comp Physiol 259: R842-R848, 1990.
8. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 65: 40-51, 2005.
9. Caulfield MP. Muscarinic receptors- characterization, coupling and function. Pharmacol Ther 58: 319-379, 1993.
10. Chan CY, Chen YS, Lee HH, Huang HS, Lai YL, Chen CF, Ma MC. Erythropoietin protects post-ischemic hearts by preventing extracellular matrix degradation: role of Jak2-ERK pathway. Life Sci 81: 717-723, 2007.
11. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101: 1833-1839, 2000.
12. Cohn JN. Abnormalities of peripheral sympathetic nervous system control in congestive heart failure. Circulation 82: I59-I67, 1990.
13. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 98: 1329-1334, 1998.
14. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med 12: 97-101, 2002.
15. Dabrowska B, Dabrowski A, Skrobowski A. Parasympathetic withdrawal precedes spontaneous blood pressure elevations in women with primary hypertension. Cardiology 87: 119-124, 1996.
16. Dall'ago P, D'Agord Schaan B, da Silva VO, Werner J, da Silva Soares PP, de Angelis K, Irigoyen MC. Parasympathetic dysfunction is associated with baroreflex and chemoreflex impairment in streptozotocin-induced diabetes in rats. Auton Neurosci 131: 28-35, 2007.
17. Dambrink JH, Tuininga YS, van Gilst WH, Peels KH, Lie KI, Kingma JH. Association between reduced heart rate variability and left ventricular dilatation in patients with a first anterior myocardial infarction. CATS Investigators Captopril and Thrombolysis Study. Br Heart J 72: 514-520, 1994.
18. Dhein S, van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res 44: 161-182, 2001.
19. Du XJ, Cox HS, Dart AM, Esler MD. Depression of efferent parasympathetic control of heart rate in rats with myocardial infarction: effect of losartan. J Cardiovasc Pharmacol 31: 937-944, 1998.
20. Esparza J, Vilardell C, Calvo J, Juan M, Vives J, Urbano-Marquez A, Yague J, Cid MC. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood 94: 2754-2766, 1999.
21. Fisher JT, Vincent SG, Gomeza J, Yamada M, Wess J. Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M2 or M3 muscarinic acetylcholine receptors. FASEB J 18: 711-713, 2004.
22. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 48: 1548-1551, 2006.
23. Gehrmann J, Meister M, Maguire CT, Martins DC, Hammer PE, Neer EJ, Berul CI, Mende U. Impaired parasympathetic heart rate control in mice with a reduction of functional G protein βγ-subunits. Am J Physiol Heart Circ Physiol 282: H445-H456, 2002.
24. Girgis I, Chakko S, de Marchena E, Jara C, Diaz P, Castellanos A, Myerburg RJ. Effect of clonidine on heart rate variability in congestive heart failure. Am J Cardiol 82: 335-337, 1998.
25. Gogly B, Groult N, Hornebeck W, Godeau G, Pellat B. Collagen zymography as a sensitive and specific technique for the determination of subpicogram levels of interstitial collagenase. Anal Biochem 255: 211-216, 1998.
26. Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Brodkin J, Grinberg A, Sheng H, Wess J. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96: 1692-1697, 1999.
27. Hare JM, Keaney JF Jr, Balligand JL, Loscalzo J, Smith TW, Colucci WS. Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs. J Clin Invest 95: 360-366, 1995.
28. Henning RJ, Khalil IR, Levy MN. Vagal stimulation attenuates sympathetic enhancement of left ventricular function. Am J Physiol Heart Circ Physiol 258: H1470-H1475, 1990.
29. Julius S. Autonomic nervous system dysregulation in human hypertension. Am J Cardiol 67: 3B-7B, 1991.
30. Kass DA, Maughan WL, Guo ZM, Kono A, Sunagawa K, Sagawa K. Comparative influence of load vs. inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships. Circulation 76: 1422-1436, 1987.
31. Kinugawa T, Dibner-Dunlap ME. Altered vagal and sympathetic control of heart rate in left ventricular dysfunction and heart failure. Am J Physiol Regul Integr Comp Physiol 268: R317-R323, 1995.
32. Koglin J, Uberfuhr P, von Scheidt W. Parasympathetic denervation supersensitivity of the transplanted human ventricle in vivo. Am J Physiol Heart Circ Physiol 271: H435-H439, 1996.
33. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 351: 478-484, 1998.
34. La Rovere MT, Mortara A, Pantaleo P, Maestri R, Cobelli F, Tavazzi L. Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation 90: 838-843, 1994.
35. Langewitz W, Ruddel H, Schachinger H. Reduced parasympathetic cardiac control in patients with hypertension at rest and under mental stress. Am Heart J 127: 122-128, 1994.
36. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109: 120-124, 2004.
37. Li YF, Cornish KG, Patel KP. Alteration of NMDA NR1 receptors within the paraventricular nucleus of hypothalamus in rats with heart failure. Circ Res 93: 990-997, 2003.
38. + channel in heart. Nature 325: 321-326, 1987.
39. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald K. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 115: 888-895, 2007.
40. Miura S, Ohno I, Suzuki J, Suzuki K, Okada S, Okuyama A, Nawata J, Ikeda J, Shirato K. Inhibition of matrix metalloproteinases prevents cardiac hypertrophy induced by beta-adrenergic stimulation in rats. J Cardiovasc Pharmacol 42: 174-181, 2003.
41. Nagata K, Ye C, Jain M, Milstone DS, Liao R, Mortensen RM. Galpha(i2) but not Galpha(i3) is required for muscarinic inhibition of contractility and calcium currents in adult cardiomyocytes. Circ Res 87: 903-909, 2000.
42. Oberhauser V, Schwertfeger E, Rutz T, Beyersdorf F, Rump LC. Acetylcholine release in human heart atrium: influence of muscarinic autoreceptors, diabetes, and age. Circulation 103: 1638-1643, 2001.
43. Pedretti RF, Prete G, Foreman RD, Adamson PB, Vanoli E. Autonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade. J Cardiovasc Pharmacol 41: 671-677, 2003.
44. Porter TR, Eckberg DL, Fritsch JM, Rea RF, Beightol LA, Schmedtje JF Jr, Mohanty PK. Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations. J Clin Invest 85: 1362-1371, 1990.
45. Powell BD, Redfield MM, Bybee KA, Freeman WK, Rihal CS. Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease. Am J Cardiol 98: 116-120, 2006.
46. Redfield MM. Understanding "diastolic" heart failure. N Engl J Med 350: 1930-1931, 2004.
47. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108: 560-565, 2003.
48. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, Fabbi P, Ballestrero A, Brunelli C, Barsotti A. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: the role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 69: 736-745, 2006.
49. Stratton JR, Levy WC, Caldwell JH, Jacobson A, May J, Matsuoka D, Madden K. Effects of aging on cardiovascular responses to parasympathetic withdrawal. J Am Coll Cardiol 41: 2077-2083, 2003.
50. Studeli R, Jung S, Mohacsi P, Perruchoud S, Castiglioni P, Wenaweser P, Heimbeck G, Feller M, Hullin R. Diastolic dysfunction in human cardiac allografts is related with reduced SERCA2a gene expression. Am J Transplant 6: 775-782, 2006.
51. Szabo G, Otero AS. Muscarinic activation of potassium channels in cardiac myocytes: kinetic aspects of G protein function in vivo. Trends Pharmacol Sci, Suppl 46-49, 1989.
52. 2+ channels in mouse heart. Proc Natl Acad Sci USA 94: 1727-1732, 1997.
53. Vatner DE, Lee DL, Schwarz KR, Longabaugh JP, Fujii AM, Vatner SF, Homcy CJ. Impaired cardiac muscarinic receptor function in dogs with heart failure. J Clin Invest 81: 1836-1842, 1988.
54. Von Scheidt W, Bohm M, Stablein A, Autenrieth G, Erdmann E. Antiadrenergic effect of M-cholinoceptor stimulation on human ventricular contractility in vivo. Am J Physiol Heart Circ Physiol 263: H1927-H1931, 1992.
55. Wang GY, Bergman MR, Nguyen AP, Turcato S, Swigart PM, Rodrigo MC, Simpson PC, Karliner JS, Lovett DH, Baker AJ. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 69: 688-696, 2006.
56. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 116: 1413-1423, 2007.
57. Wess J, Duttaroy A, Zhang W, Gomeza J, Cui Y, Miyakawa T, Bymaster FP, McKinzie L, Felder CC, Lamping KG, Faraci FM, Deng C, Yamada M. M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Receptors Channels 9: 279-290, 2003.
58. Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev 85: 1159-1204, 2005.
59. Xie Z, Singh M, Singh K. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta. J Biol Chem 279: 39513-39519, 2004.
60. Yan AT, Yan RT, Spinale FG, Afzal R, Gunasinghe HR, Arnold M, Demers C, McKelvie RS, Liu PP. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 12: 514-519, 2006.
61. Zamotrinsky AV, Kondratiev B, de Jong JW. Vagal neurostimulation in patients with coronary artery disease. Auton Neurosci 88: 109-116, 2001.